ILMN Price Prediction Next Week
Technical Analysis: ILMN's stock shows significant bearish momentum with RSI at 21.89, deeply oversold territory. The MACD indicator (-10.33) displays a strong negative trend with the histogram showing continued downward pressure. Price is trading well below all major moving averages, with the 5-day SMA at 99.15 and 20-day SMA at 116.30.
News Impact:
- Carl Icahn reduced his stake in ILMN, indicating decreased institutional confidence
- Recent partnership with Broad Clinical Labs for single-cell sequencing technology development hasn't provided price support
- Multiple analysts have lowered their price targets:
- Morgan Stanley: $136
- Canaccord Genuity: $135
- Guggenheim: $150
Price Prediction for Next Week: Based on Fibonacci levels and current technical setup:
- Resistance: $111.75
- Support: $95.21
- Critical Support: $90.09
Target Price Range: $92-97 The stock is likely to continue its downward trend with potential for a minor technical bounce from oversold conditions. However, the overall sentiment remains bearish with significant overhead resistance.
Recommendation: SELL
- Current price weakness and institutional selling pressure suggest further downside
- Multiple analyst downgrades create negative sentiment
- Technical indicators show strong bearish momentum
- Entry for short positions around $98-100 with initial target at $92
ILMN Similar Chart Price Prediction
The price of ILMN is predicted to go up 9.91%, based on the high correlation periods with LYG. The similarity of these two price pattern on the periods is 99.19%.
ILMN
LYG
Up: 9.91%Similarity: 99.19%
ILMN Revenue Forecast
ILMN EPS Forecast
ILMN FAQs
What is bull’s view on ILMN?
What is bear's view on ILMN?
What is ILMN revenue forecast for next quarter？
What is ILMN eps forecast for next quarter？
ILMN VS S&P500
Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth opportunities for Illumina with or without Grail.
Illumina's very large installed base of sequencing instruments should translate into significant ongoing sales of high-margin consumables and maintenance services.
Illumina's financial health appears solid, despite some potential outflows that may required above and beyond its debt obligations, such as the potential EU frontrunning fine.
ILMN Analyst's Forecast
David Westenberg
Piper Sandler
Buy
2025-02-10
Price Target
$185 → $190
Upside
+86.68%
Piper Sandler analyst David Westenberg raised the firm's price target on Illumina to $190 from $185 following quarterly results. The firm keeps an Overweight rating on the shares.
Luke Sergott
Barclays
Hold → Sell
2025-02-10
Price Target
$130 → $100
Downside
-1.75%
Patrick Donnelly
Citigroup
Strong Buy → Hold
2024-12-11
Price Target
$190 → $165
Upside
+14.69%
